Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced the closing of its previously announced non-brokered private placement with Sorbie Bornholm LP and Sorbie Investments LLP, representing a notional subscription amount of approximately CAD$5 million. The financing included the issuance of 7.94 million units at a notional price of CAD$0.63 per unit, with each unit consisting of one common share and one warrant exercisable at CAD$0.77 for three years. The proceeds will be made available to the company through an 18-month sharing arrangement tied to the volume-weighted average trading price of its shares, with monthly settlement amounts varying based on market performance.
Onco-Innovations said it intends to use the net proceeds received under the sharing arrangement to advance development of its ONC010 program, including manufacturing and preclinical activities, support continued development of its SynoGraph platform and provide working capital for general corporate purposes. This capital infusion is critical for the company as it progresses its pipeline of oncology therapies. The ONC010 program targets solid tumors, leveraging patented technology for which Onco-Innovations has secured an exclusive worldwide license. The SynoGraph platform is a novel approach to cancer treatment, though details remain under development.
The private placement structure, which ties settlement amounts to share price performance, mitigates dilution risk for existing shareholders while providing the company with flexible access to capital. This financing strategy aligns with the company's goal of advancing its research without immediate pressure on its cash position. Onco-Innovations, a Canadian-based company dedicated to cancer research and treatment, specializes in oncology and aims to pursue the prevention and treatment of cancer through pioneering research and innovative solutions.
Investors and stakeholders can monitor the company's progress through its newsroom at https://ibn.fm/ONNVF. The full press release detailing the private placement is available at https://ibn.fm/1Hrlg. This financing represents a significant vote of confidence from institutional investors in Onco-Innovations' strategic direction and the potential of its oncology programs.
